Corcept.

Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward-Looking Statements.Cortisol. Cortisol is a hormone that modulates many physiological and psychological processes. Because of its central role in the body’s response to stress, cortisol is most commonly known as the stress hormone. It plays a key role in regulating metabolism and maintaining normal blood pressure. It affects both cognition and emotional state.Corcept Therapeutics is developing next-generation, selective glucocorticoid receptor II (GR II) antagonists for the treatment of psychiatric disorders and.Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol receptor blocker, is indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with ...

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) was the recipient of a large decrease in short interest in October. As of October 31st, there was short interest totalling 14,120,000 shares, a decrease of 5.6% from the October 15th total of 14,960,000 shares. Currently, 16.1% of the shares of the stock are sold short.WebCorcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...Web

November 2023 – PROPRIETARY – Do not republish, redistribute or modify without Corcept’s express written permission This presentation contains forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended, and the Securities Act of 1933, as amended.

The Corcept name, the Corcept logo, and all related names, logos, product, and service names, designs and slogans, whether appearing in large print or with the trademark symbol, are the trademarks or trade dress of Corcept in the US and other countries. 6.3 Ownership of Feedback.27 Des 2021 ... The case arose incident to ANDA litigation between the parties involving Corcept's Korlym product comprising the active pharmaceutical ...About Corcept Therapeutics. For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients across a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept’s advanced clinical trials are being conducted in patients with hypercortisolism ...WebCorcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...WebCorcept Therapeutics Incorporated (NASDAQ:CORT) posted its earnings results on Wednesday, November, 1st. The biotechnology company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.06. The biotechnology company earned $123.60 million during the quarter, compared to analyst estimates of $119. ...

Feb 13, 2023 · Under the proposed settlement, Corcept has agreed to make a one-time payment of $14.0 million, which will be covered in full by Corcept’s insurers. About Corcept Therapeutics

7 Des 2021 ... Corcept Thera- peutics, Inc., PGR2019-00048, 2020 WL 6809812 (P.T.A.B.. Nov. 18, 2020) (Final Decision). Teva appeals, arguing the. Board ...

Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...WebDec 31, 2021 · MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial stage company engaged in the discovery, development and sale of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2021. Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome.Mar 30, 2022 · About Corcept’s Ovarian Cancer Program. The data in this release come from Corcept’s 178-patient, randomized, controlled, Phase 2 trial of relacorilant plus nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. 5 The women who entered the trial had experienced disease progression on prior lines of therapy. The median ... Jun 30, 2022 · Corcept’s second quarter 2022 revenue was $103.4 million, compared to $91.6 million in the second quarter of 2021. Second quarter operating expenses were $72.0 million , compared to $59.6 million in the second quarter of 2021, due to increased clinical trial activity, expenses to support the expansion of our clinical development and ...

Oval shaped, light yellow to yellow tablets debossed with “Corcept” on one side and “300” on the other side. The tablets are not scored. 4 CONTRAINDICATIONS KORLYM is contraindicated in: • Pregnancy [See Dosage and Administration (2.1), Use in Specific Populations (8.1,8.3)]WebJul 26, 2023 · November 1, 2023. Corcept Appoints Monica Tellado as President, Emerging Markets. October 26, 2023. Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH) October 25, 2023. Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call. August 2, 2023. Feb 28, 2023 · Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward-Looking Statements. About Corcept. Executive Team. Board of Directors. Educational Grants. Contact Us. 149 Commonwealth Drive, Menlo Park, CA 94025. Phone: 650-327-3270. Email: [email protected]. Contact us with questions about Corcept, for more information about the company, or where we are located. Corcept prides itself on a dynamic culture which remains true to its values while embracing continued growth and change. Our work is marked by innovation, integrity, rigor, transparent communication, and collaboration. We all have unique contributions to make, and our success is the sum of those contributions. Join us!

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders.

The Clinical Trial Manager (CTM) will independently manage all clinical aspects of a medium to large clinical study or up to two smaller clinical studies. This role will work closely with cross functional teams, vendors, sites and CRO (when applicable) to ensure compliance with protocol and the overall clinical objective.Institutional Trading of Corcept Therapeutics. A number of hedge funds have recently added to or reduced their stakes in the stock. Diversified Trust Co acquired a new stake in Corcept Therapeutics during the 3rd quarter worth approximately $254,000. Morgan Stanley lifted its position in Corcept Therapeutics by 31.9% during the 3rd quarter.WebAbout Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with …WebCorcept Therapeutics Incorporated (NASDAQ:CORT) posted its earnings results on Wednesday, November, 1st. The biotechnology company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.06. The biotechnology company earned $123.60 million during the quarter, compared to analyst estimates of $119. ...Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Additional Information Regarding the ...In accordance with the terms and conditions of the Tender Offer, based on the final count, Corcept has accepted for purchase 6,610,369 shares of common stock at a purchase price of $22.00 per ...

Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ...

Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Additional Information Regarding the ...

A class action complaint has been filed against Corcept, which alleges that defendants made materially false and/or misleading statements, and failed to ...Corcept’s fourth quarter 2022 revenue was $103.1 million, compared to $98.8 million in the fourth quarter of 2021. Revenue for the full year was $401.9 million, compared to $366.0 million in 2021. The company expects 2023 revenue of $430 – $450 …Corcept Therapeutics Incorporated (. CORT Quick Quote. CORT - Free Report) reported third-quarter 2023 earnings of 28 cents per share, which beat the Zacks Consensus Estimate of 22 cents. The ...Corcept’s advanced clinical trials are being conducted in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and liver disease (NASH).In accordance with the terms and conditions of the Tender Offer, based on these preliminary results, Corcept expects to purchase 6,630,151 shares of common stock at a purchase price of $22.00 per ...Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...WebMENLO PARK, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat ...WebCorcept Therapeutics announced the preliminary results of its previously announced tender offer to purchase up to 7,500,000 shares of its common stock, par value $0.001 per share, at a price not greater than $22.00 nor less than $19.25 per share, in cash, less any applicable withholding taxes and without interest, which expired one minute after ...7 Des 2021 ... Corcept Thera- peutics, Inc., PGR2019-00048, 2020 WL 6809812 (P.T.A.B.. Nov. 18, 2020) (Final Decision). Teva appeals, arguing the. Board ...Dec 1, 2023 · Cafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more. On November 2, 2023, Joseph Lyon, the Chief Accounting Officer of Corcept Therapeutics Inc (NASDAQ:CORT), sold 5,000 shares of the company. Find the latest Corcept Therapeutics Incorporated (CORT ...

MENLO PARK, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism and neurology disorders by modulating the effects of the hormone cortisol, today …WebCorcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat ...Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...Instagram:https://instagram. ltry stock forecasttarget affirmswing trade alertswhere can i paper trade options MENLO PARK, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat ... vending machine costcodow apple Institutional Trading of Corcept Therapeutics. A number of hedge funds have recently added to or reduced their stakes in the stock. Diversified Trust Co acquired a new stake in Corcept Therapeutics during the 3rd quarter worth approximately $254,000. Morgan Stanley lifted its position in Corcept Therapeutics by 31.9% during the 3rd quarter.Web tmboile stock Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common Stock. March 6, 2023 at 8:00 AM EST. MENLO PARK, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics …Corcept is a biopharmaceutical company that develops cortisol modulators, drugs that block the glucocorticoid receptor (GR) and reduce cortisol levels. Corcept's products are designed to treat endocrine, metabolic, oncologic, and psychiatric disorders, such as diabetes, cancer, and depression.